Antibiotic allergy labels, especially to penicillins, are common but often inaccurate, with more than 90% disproven on formal evaluation. These unverified labels lead to suboptimal antibiotic use, increased health care costs, and worse clinical outcomes. Traditional allergist-led assessment models are not scalable due to global shortages of allergy specialists. Recent evidence supports a shift toward proactive, ambulatory, multidisciplinary delabeling strategies that integrate risk-stratified direct oral drug provocation testing into routine care. Validated point-of-care tools now enable nonallergists, including pharmacists, nurses, and physicians, to safely identify low-risk patients suitable for delabeling without skin testing. Successful programs in hospitals, outpatient clinics, and community settings demonstrate that ambulatory delabeling is safe, cost-effective, and scalable. High-yield populations such as pregnant women, immunocompromised individuals, and older adults benefit significantly from timely evaluation. Effective implementation requires structured training, standardized protocols, integration into electronic health records, and a Hub-and-Spoke model linking nonspecialist “spokes” to allergist-led “hubs” for oversight. Clear documentation, patient education, and postchallenge follow-up are essential to prevent relabeling. Future efforts must focus on equitable access, workforce development, and research to validate tools in underrepresented populations and quantify long-term antimicrobial stewardship benefits. Ambulatory delabeling is no longer the sole domain of allergists but a shared responsibility across health care systems to improve prescribing, patient safety, and global antimicrobial resistance outcomes.
A blog that publishes updates and open access scientific papers about allergy, asthma and immunology. Editor: Juan Carlos Ivancevich, MD. Specialist in Allergy & Immunology
May 16, 2026
Novel Approaches to Ambulatory Antibiotic Allergy Clinics.
Cox F, Dowden A, Sousa-Pinto B, Li PH. J Allergy Clin Immunol Pract. 2026 May;14(5):1014-1022.e1. doi: 10.1016/j.jaip.2025.12.013.
Abstract
Antibiotic allergy labels, especially to penicillins, are common but often inaccurate, with more than 90% disproven on formal evaluation. These unverified labels lead to suboptimal antibiotic use, increased health care costs, and worse clinical outcomes. Traditional allergist-led assessment models are not scalable due to global shortages of allergy specialists. Recent evidence supports a shift toward proactive, ambulatory, multidisciplinary delabeling strategies that integrate risk-stratified direct oral drug provocation testing into routine care. Validated point-of-care tools now enable nonallergists, including pharmacists, nurses, and physicians, to safely identify low-risk patients suitable for delabeling without skin testing. Successful programs in hospitals, outpatient clinics, and community settings demonstrate that ambulatory delabeling is safe, cost-effective, and scalable. High-yield populations such as pregnant women, immunocompromised individuals, and older adults benefit significantly from timely evaluation. Effective implementation requires structured training, standardized protocols, integration into electronic health records, and a Hub-and-Spoke model linking nonspecialist “spokes” to allergist-led “hubs” for oversight. Clear documentation, patient education, and postchallenge follow-up are essential to prevent relabeling. Future efforts must focus on equitable access, workforce development, and research to validate tools in underrepresented populations and quantify long-term antimicrobial stewardship benefits. Ambulatory delabeling is no longer the sole domain of allergists but a shared responsibility across health care systems to improve prescribing, patient safety, and global antimicrobial resistance outcomes.
Antibiotic allergy labels, especially to penicillins, are common but often inaccurate, with more than 90% disproven on formal evaluation. These unverified labels lead to suboptimal antibiotic use, increased health care costs, and worse clinical outcomes. Traditional allergist-led assessment models are not scalable due to global shortages of allergy specialists. Recent evidence supports a shift toward proactive, ambulatory, multidisciplinary delabeling strategies that integrate risk-stratified direct oral drug provocation testing into routine care. Validated point-of-care tools now enable nonallergists, including pharmacists, nurses, and physicians, to safely identify low-risk patients suitable for delabeling without skin testing. Successful programs in hospitals, outpatient clinics, and community settings demonstrate that ambulatory delabeling is safe, cost-effective, and scalable. High-yield populations such as pregnant women, immunocompromised individuals, and older adults benefit significantly from timely evaluation. Effective implementation requires structured training, standardized protocols, integration into electronic health records, and a Hub-and-Spoke model linking nonspecialist “spokes” to allergist-led “hubs” for oversight. Clear documentation, patient education, and postchallenge follow-up are essential to prevent relabeling. Future efforts must focus on equitable access, workforce development, and research to validate tools in underrepresented populations and quantify long-term antimicrobial stewardship benefits. Ambulatory delabeling is no longer the sole domain of allergists but a shared responsibility across health care systems to improve prescribing, patient safety, and global antimicrobial resistance outcomes.
Subscribe to:
Post Comments (Atom)


No comments:
Post a Comment